VERV - Verve Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

VERV is currently covered by 7 analysts with an average price target of $22.16. This is a potential upside of $11.14 (101.09%) from yesterday's end of day stock price of $11.02.

Verve Therapeutics's activity chart (see below) currently has 17 price targets and 38 ratings on display. The stock rating distribution of VERV is 20.83% HOLD and 79.17% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 12.04% with an average time for these price targets to be met of 15.22 days.

Highest price target for VERV is $15, Lowest price target is $13, average price target is $18.33.

Most recent stock forecast was given by KOSTAS BILIOURIS from BMO on 27-Jun-2025. First documented stock forecast 12-Jul-2021.

Currently out of the existing stock ratings of VERV, 5 are a HOLD (20.83%), 19 are a BUY (79.17%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$13.5

$2.47 (22.39%)

$30

18 days ago
(27-Jun-2025)

0/3 (0%)

$2.2 (19.47%)

Buy

$13.5

$2.47 (22.39%)

$25

27 days ago
(18-Jun-2025)

0/7 (0%)

$2.38 (21.40%)

Buy

$13

$1.97 (17.86%)

$39

28 days ago
(17-Jun-2025)

0/7 (0%)

$1.62 (14.24%)

Hold

$22

3 months ago
(15-Apr-2025)

1/3 (33.33%)

$9 (69.23%)

8

Buy

$15

$3.97 (35.99%)

$17

4 months 11 days ago
(04-Mar-2025)

0/7 (0%)

$8.83 (143.11%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is VERV (Verve Therapeutics) average time for price targets to be met?

On average it took 15.22 days on average for the stock forecasts to be realized with a an average price target met ratio 12.04

Which analyst has the current highest performing score on VERV (Verve Therapeutics) with a proven track record?

ETZER DAROUT

Which analyst has the current lower performing score on VERV (Verve Therapeutics) with a proven track record?

ERIC JOSEPH

Which analyst has the most public recommendations on VERV (Verve Therapeutics)?

Etzer Darout works at BMO and has 12 price targets and 8 ratings on VERV

Which analyst is the currently most bullish on VERV (Verve Therapeutics)?

Dae Gon Ha with highest potential upside - $44.97

Which analyst is the currently most reserved on VERV (Verve Therapeutics)?

Etzer Darout with lowest potential downside - -$0

Verve Therapeutics in the News

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON , May 02, 2025 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted equity awards to seven new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?